With atypical antipsychotics for the control group, evaluate cognitive function in schizophrenia patients with antipsychotics combined 5-Hydroxytryptamine 1A (5-HT1A) receptor partial agonist tandospirone
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnostic and Statistical Manual of Mental Disorders-IV Edition (DSM-IV) diagnostic criteria for schizophrenia patients.
18-65 years (including 18 and 65), male or female.
Treated with a stable dose of an AAPD for at least three months.
Informed consent was obtained (if the patient is in the acute phase of schizophrenia, does not have the capacity, their guardians need sign informed consent).
PANSS negative score ≤60.
You may not be if
Combined AxisⅠmental illness other than schizophrenia;
Taking a mood stabilizer, antidepressants, anticholinergic or anxiolytic drugs, and other drugs improve cognitive function;
Suicidal tendencies;
Have severe or unstable heart, liver, kidney, endocrine, blood and other medical disease patients
Clinically significant ECG or laboratory abnormalities were
Glaucoma and epilepsy;
Unsupervised or unable to take prescribed medication;
History of alcohol and drug abuse;
Allergic;
Pregnant or lactating woman;
Patients participate in other clinical trials during a month;
Clareo Health | Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia
